Competition
Competitive Bottom Line
ConvaTec has a real but uneven moat, not a uniform one. The strongest, most defensible economics sit in the two franchises the market under-appreciates — 180 Medical (US continence home-delivery) and Infusion Care (the only scaled OEM of tubed-pump infusion sets, locked into long-term contracts with Tandem, Medtronic and Ypsomed). The structural weakness is in Advanced Wound Care, where Smith+Nephew's own 2025 Annual Report puts ConvaTec at only 6% of a $13.1B AWM market versus SNN 14%, Solventum 14%, Mölnlycke 10% — a sub-scale share in a market about to be reset by the January 2026 CMS skin-substitute fee schedule. The one competitor that matters most is Coloplast: most direct economic substitute, structural margin benchmark (FY24/25 EBIT 28%, ~26% adj op margin vs CTEC 22.3%), and — critically — a stock down ~38% in twelve months as Coloplast digests Heylo write-downs, an Interventional Urology recall, and a China dressings return. Coloplast's stumble is the rarest asset CTEC has: a benchmark peer that just ran into the kinds of self-inflicted issues CTEC has spent five years cleaning up.
The Right Peer Set
Only Coloplast is a clean economic substitute; two listed peers (SOLV, SNN) are larger but more diversified; PODD is the demand-side disruptor of Infusion Care; IART is a wound-recon biologics adjacency in distress. Three of the most relevant competitors — Mölnlycke, Hollister, B. Braun — are private and never appear in any peer screen. Smith+Nephew's own 2025 Annual Report names Mölnlycke, Coloplast and ConvaTec as its principal AWC dressing competitors and Solventum as the NPWT incumbent it is challenging — the listed peer set is therefore corroborated by competitor disclosure, not just analyst convention.
Notes: Coloplast values are in USD millions converted at DKK→USD 0.1572 (2026-05-07 close). Smith+Nephew and ConvaTec are UK-domiciled but report in USD. Sources: Yahoo Finance / StockAnalysis.com snapshot pages dated 2026-05-04 to 2026-05-09. Coloplast organic growth shown is FY24/25 reported (Coloplast FY ends Sept). PODD organic growth is FY2025 reported.
The chart sorts the peer set into three economic archetypes. Coloplast is the structural margin benchmark CTEC is trying to converge on. Insulet defines the upside on growth in any pure tubeless-pump franchise — and the precise risk to CTEC Infusion Care. Solventum and Smith+Nephew are diversified medsurg comparables — informative on margin shape, less on growth dynamics. Integra is the cautionary tale: a biologic-tilted wound-recon peer trading at $1.1B mkt cap after a 2025 MediHoney recall and an open December-2024 Boston Warning Letter.
The listed peer set understates competitive intensity. Mölnlycke alone holds an estimated 10% of the $13.1B AWM market per Smith+Nephew's own 2025 disclosure — bigger than ConvaTec's 6% share — and never appears on a screen. Hollister owns roughly the same global ostomy share as CTEC. Read the listed comp for direction; do not assume it captures the playing field.
Where The Company Wins
ConvaTec wins in places that are hard to see from a financial screen. Four advantages stand out, each with primary-source evidence.
1. 180 Medical: a structural channel asset peers cannot replicate quickly
180 Medical is the largest US direct-to-patient continence supplier, acquired by ConvaTec in 2018. It now delivers 59% of US continence sales as ConvaTec own-brand, up from ~50% pre-FISBE — an unusual feat because home-delivery distributors typically sell whatever payer-approved brand the patient chooses. Coloplast and Hollister have stronger DTC brands but neither has a comparable in-house US distribution arm of this scale. Replicating it would cost a competitor 3-5 years and a meaningful acquisition.
2. #1 OEM globally for tubed-pump infusion sets — long-dated customer locks
CTEC's Infusion Care franchise supplies the infusion sets that go into pumps from Tandem, Medtronic and Ypsomed. The franchise grew 12.5% organic in FY2025, and ConvaTec is allocating its FY2026 growth-capex envelope (8-9% of revenue, ~$135-165M) heavily to expand Infusion Care capacity, underwritten by binding customer commitments. Insulet's Omnipod (24% growth) is the long-term threat, but Insulet competes for the patient (tubeless), not the SKU (tubed) — the in-place tubed-pump installed base continues to grow in absolute terms. PODD's 10-K notes that "approximately 40% of the type 1 diabetes population in the United States and 25% of the international type 1 diabetes population use insulin pump therapy", leaving a large untapped patient pool that supports both tubed and tubeless growth for the next 5-7 years.
3. Polymer / adhesive science platform shared across four franchises
The four franchises share one R&D base ($111M FY2025), one global salesforce, one regulatory engine, and 5 manufacturing plants. Hydrocolloids, silicones, and skin-contact adhesives qualified for one franchise transfer to others — pilot lines for ostomy adhesives become wound-care lines, and so on. None of the listed peers shares this combination: SOLV is broken across MedSurg / Dental / Health IT post-spin; SNN's $1.79B AWM business is one leg of an orthopaedics-led portfolio; Coloplast is closer in shape but lacks Infusion Care exposure entirely.
4. The InnovaMatrix-adjusted growth rate is faster than every focused listed peer
Strip out the InnovaMatrix LCD shock and CTEC printed 6.4% organic growth in FY2025, against Coloplast's 4.0% (FY24/25), Solventum's 3.3% (FY25, 2-3% guided FY26), and Smith+Nephew's underlying 5.6% AWM. Only Insulet (24%) is faster, and Insulet is a single-product, single-segment business. Among the diversified chronic-care peer set, CTEC is the fastest-growing scaled name on a clean basis — yet trades at a meaningful EV/EBITDA discount to Coloplast.
Competitive scorecard - peer relative strength by dimension (0 = no presence, 10 = leader)
Reading the scorecard: CTEC scores 9-10 on three dimensions (continence channel, Infusion OEM, AWC pipeline), but 6 or below on three (ostomy share, NPWT presence, biologic AWC). The investable thesis is that the strong dimensions are bigger than the weak ones — and that the weak ones are getting less weak (the structural margin gap to Coloplast halved between 2021 and 2025).
Where Competitors Are Better
ConvaTec is genuinely behind in three places, each with named-competitor evidence.
1. Coloplast structurally earns ~400 bps more on operating margin
Coloplast prints 26% adjusted operating margin versus CTEC's 22.3%, on a revenue base nearly double the size. The gap is part mix (Coloplast skews ~70% to ostomy/continence where pricing is anchored by patient-stickiness) and part scale (DKK 27.9B revenue base, 28% reported FY24/25 EBIT margin per the conference-call deck). Coloplast's gross margin is 67.9% versus CTEC's 56.2% — closing the 12-point gross-margin gap is hard because it is mostly mix; closing the 4-point operating-margin gap is mostly cost and is what FISBE+Accelerate is engineered to achieve. The Coloplast benchmark is the most credible peg for what a focused chronic-care consumables business can earn at scale.
2. Solventum's V.A.C. NPWT incumbency in the $3.8B sub-segment
Solventum's MedSurg segment (57.9% of FY25 revenue) is the NPWT incumbent. Smith+Nephew's own 2025 Annual Report describes itself as "the primary challenger to Negative Pressure Wound Therapy incumbent Solventum" — meaning SNN, not CTEC, is the credible #2 in NPWT. Solventum's FY25 organic was only 3.3% (and Q4 AWC was +1.7% with V.A.C.-led NPWT growth offset by AWD weakness from SKU exits and back orders) but the V.A.C. franchise is sticky — Solventum closed the $725m Acera Surgical acquisition in December 2025 to add synthetic tissue to the same Wound Care business and is launching V.A.C. Peel and Place. CTEC's NPWT presence is sub-scale, and the segment is one of the bigger growth pools in AWC.
3. Insulet is taking share of new pump starts and has multi-CGM optionality
Insulet's Omnipod 5 is now in 19 countries with type-2 indication added Aug-2024; Omnipod platform is in 25 countries. Multi-CGM integration includes Dexcom G7 (US iOS, all of Europe) and Abbott FreeStyle Libre 2 Plus (Australia). The next generation Omnipod 6 is in development; the STRIVE pivotal study completed in 2025; EVOLUTION 2 for Fully Closed Loop Type-2 has enrolled. PODD revenue grew 24% organic in FY2025 with 5,400 employees (+38% YoY) and a third manufacturing plant being built in Costa Rica. PODD does not compete with CTEC on the same SKU; it competes for the patient. Each new patient who picks Omnipod over a Tandem/Medtronic tubed pump is a patient who never buys a CTEC infusion set. The CTEC mitigant is contracted capacity underwritten by long-term customer commitments and a still-growing tubed-pump absolute installed base — but the share-of-new-starts curve is moving against CTEC.
4. Smith+Nephew quantifies CTEC at only 6% of AWM, behind SNN, SOLV, and Mölnlycke
SNN's 2025 Annual Report puts the AWM market at $13.1B (+4% in 2025) and discloses a peer-share split: SNN 14%, Solventum 14%, Mölnlycke 10%, ConvaTec 6%, Others 56%. Even allowing for this being SNN's own internal estimate, it places CTEC fourth in scale, behind two listed peers and one private peer. CTEC's AWC franchise is roughly a third of group revenue, so a sub-scale share matters — particularly into the 2026 CMS skin-substitute fee schedule reset at $127.28 per cm² that hits Cellular and Tissue Products across the industry.
Threat Map
The competitive threats sort cleanly by timing: a 2026 reimbursement reset that hits the whole industry; an Insulet share-shift that plays out 5-7 years; private-peer pressure that is constant background; and Solventum's NPWT incumbency that is durable but slow-moving.
The single-largest near-term threat is the CMS skin-substitute fee schedule — but it is not a CTEC-specific event. Coloplast's Kerecis (24% organic growth in FY24/25), SNN's GRAFIX biologics, and IART's Integra Skin / PriMatrix / Amnio range all sit on the same regulator-determined cliff. CTEC has already taken the impairment; some peers have not. That asymmetry is one of the few places where being first to take the hit is an advantage.
Moat Watchpoints
Five measurable signals will tell the investor whether ConvaTec's competitive position is improving or weakening. Read these every six months.
The investable competitive question is not whether ConvaTec dominates a market — it does not. It is whether the three franchises where it has a real moat (Continence DTC, Infusion OEM, polymer-platform synergy) compound faster than the two franchises where it is sub-scale (NPWT, biologic AWC) drag. The 2025 evidence — 6.4% ex-InnovaMatrix organic growth, first new US GPO in five years, 180 Medical own-brand mix at 59%, Infusion +12.5% — supports that read. The 2026 test is whether those signals hold once the InnovaMatrix LCD reset clears and Coloplast starts to recover from its self-inflicted issues.